首页> 外文期刊>Toxicological sciences: An official journal of the Society of Toxicology >Human 3D Gastrointestinal Microtissue Barrier Function As a Predictor of Drug-Induced Diarrhea
【24h】

Human 3D Gastrointestinal Microtissue Barrier Function As a Predictor of Drug-Induced Diarrhea

机译:人类3D胃肠道微囊屏障功能作为药物引起的腹泻的预测因子

获取原文
获取原文并翻译 | 示例
           

摘要

Drug-induced gastrointestinal toxicities (GITs) rank among the most common clinical side effects. Preclinical efforts to reduce incidence are limited by inadequate predictivity of in vitro assays. Recent breakthroughs in in vitro culture methods support intestinal stem cell maintenance and continual differentiation into the epithelial cell types resident in the intestine. These diverse cells self-assemble into microtissues with in vivo-like architecture. Here, we evaluate human GI microtissues grown in transwell plates that allow apical and/or basolateral drug treatment and 96-well throughput. Evaluation of assay utility focused on predictivity for diarrhea because this adverse effect correlates with intestinal barrier dysfunction which can be measured in GI microtissues using transepithelial electrical resistance (TEER). A validation set of widely prescribed drugs was assembled and tested for effects on TEER. When the resulting TEER inhibition potencies were adjusted for clinical exposure, a threshold was identified that distinguished drugs that induced clinical diarrhea from those that lack this liability. Microtissue TEER assay predictivity was further challenged with a smaller set of drugs whose clinical development was limited by diarrhea that was unexpected based on 1-month animal studies. Microtissue TEER accurately predicted diarrhea for each of these drugs. The label-free nature of TEER enabled repeated quantitation with sufficient precision to develop a mathematical model describing the temporal dynamics of barrier damage and recovery. This human 3D GI microtissue is the first in vitro assay with validated predictivity for diarrhea-inducing drugs. It should provide a platform for lead optimization and offers potential for dose schedule exploration.
机译:药物诱导的胃肠道毒性(GITS)排名在最常见的临床副作用中。减少发病率的临床前努力受到体外测定的不足预测性的限制。体外培养方法最近的突破支持肠道干细胞维持和持续分化到肠内静脉曲张的上皮细胞类型。这些不同的细胞以体内架构自组装成微发射。在这里,我们评估在Transwell平板中生长的人GI微发布,允许顶端和/或基石药物治疗和96孔通过产量。测定效果的评估专注于腹泻的预测性,因为这种不良反应与肠道阻隔功能障碍相关,其可以使用Transepearial电阻(TEER)在GI微观发布中测量。组装并测试了一套验证的广泛规定的药物,用于对人权的影响。当调整所产生的抗议抑制效力进行临床暴露时,确定了阈值,即诱导患有缺乏这一责任的临床腹泻的杰出药物。 Microtissue Teer测定预测性进一步挑战,较小的药物,临床发育受腹泻的限制,基于1个月的动物研究。 Microtissue Teer准确地预测了每种药物的腹泻。 TEER的无标签性质使重复定量具有足够的精度来开发描述障碍损坏时间动态和恢复的数学模型。这种人3D GI Microtissue是第一个体外测定,具有验证腹泻诱导药物的预测性。它应该为铅优化提供平台,并提供剂量安排勘探的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号